atrial fibrillation
Conditions
Interventions
Dapagliflozin group:N/A
control group:N/A
Sponsors
Beijing Anzhen Hospital, Capital Medical University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Over 18 years old; 2. Simple surgical CoxMazeIV surgical ablation (simple persistent or long-term persistent atrial fibrillation drug treatment is not effective, and medical catheter ablation fails or is not suitable) 3. Cardiac organic disease combined with persistent or long-term persistent atrial fibrillation requires cardiac surgery and CoxMazeIV surgical ablation; 4. Able and willing to comply with all preliminary and subsequent reviews and requirements; 5. Sign the informed consent form.
Exclusion criteria
Exclusion criteria: 1. Dapagliflozin allergy; 2. Hyperthyroidism; 3. Acute myocardial infarction, acute stroke, or other vascular diseases requiring intervention within 6 months before the operation; 4. Received cardiac surgery within 3 months before the surgery; 5. Glomerular filtration rate 65 mm.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Recurrence of atrial fibrillation 6 months after surgery; | — |
Secondary
| Measure | Time frame |
|---|---|
| Recurrence of atrial fibrillation 12 months after surgery;Cardiovascular complex adverse events (cardiac death, new heart failure, malignant arrhythmia, stroke); | — |
Countries
China
Contacts
Public ContactXiubin Yang
Beijing Anzhen Hospital, Capital Medical University
Outcome results
None listed